Richard Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)

Court up­holds Ab­b­Vie's patents on block­buster can­cer drug Im­bru­vi­ca, gener­ics un­like­ly un­til 2032

Ab­b­Vie’s block­buster can­cer drug Im­bru­vi­ca may hold on­to its mo­nop­oly for at least an­oth­er decade, thanks to a court rul­ing Thurs­day that found a gener­ic drug­mak­er’s Im­bru­vi­ca knock­off in­fringed on Ab­b­Vie’s patents.

The Delaware dis­trict court found that Alvo­gen, whose sub­sidiary Alvotech is al­so still go­ing af­ter Ab­b­Vie’s oth­er mas­sive block­buster drug Hu­mi­ra in Illi­nois dis­trict court, made claims on par­tic­u­lar Im­bru­vi­ca patents that “are not in­valid” and Alvo­gen “in­fringes each of the as­sert­ed claims.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.